Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. (Q45761321)
Jump to navigation
Jump to search
scientific article published in January 1997
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. |
scientific article published in January 1997 |
Statements
Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity (English)
Gordon M
Deeks S
De Marzo C
Goodgame J
Guralnik M
Lang W
Mimura T
Pearce D
1 January 1997